Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infectious diseases. Its work centers on advancing innovative therapeutic candidates and related research tools that support discovery, preclinical development, and clinical development. Precigen also operates through business segments that include biopharmaceutical activities and specialized research-model services, giving it a broad presence across therapeutic development and life-science applications. Headquartered in Germantown, Maryland, Precigen serves as a clinical-stage innovator in the biotechnology sector, with an emphasis on translating proprietary technology platforms into potential treatments for patients with unmet medical needs.
Website20374 Seneca Meadows Parkway
Germantown, MD, 20876
United States
What share of all stock conversation is about PGEN?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about PGEN that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% 0 | 86.05% +28.15 | 78.33% -7.11 | 83.22% -2.78 | ||
| Bearish | 0% 0 | 13.95% -28.15 | 21.67% +7.11 | 16.78% +2.78 |
Of the messages about PGEN that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 53.13% | 28.57% | 23.95% | ||
| Technical Analysis | — | 1.56% | 33.74% | 16.32% | ||
| Earnings | — | 0% | 2.71% | 3.46% | ||
| Analysts | — | 45.31% | 34.98% | 23.44% | ||
| Controversies | — | 0% | 0% | 0.31% | ||
| Macro | — | 0% | 0% | 32.51% |
Of the messages about PGEN, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 85.71% | 61.43% | 54.56% | 65.74% | ||
| Newcomers | 14.29% | 38.57% | 45.44% | 34.26% |
Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]
Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...
Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.
Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...
Investors talking about PGEN also mention
| # | Name | Attention |
|---|---|---|
| 1 | Alaunos Therapeutics Inc.TCRT | 0%new |
| 2 | uniQure N.V.QURE | 0.02%+0.01 |
| 3 | Arcus Biosciences, Inc.RCUS | 0%new |
| 4 | Kulicke & Soffa Industries, Inc.KLIC | 0%0 |
| 5 | Cullinan Therapeutics Inc.CGEM | 0%new |
| 6 | Nurix Therapeutics, Inc.NRIX | 0%new |
| 7 | Relay Therapeutics Inc.RLAY | 0%new |
| 8 | Kymera Therapeutics Inc.KYMR | 0%0 |
| 9 | Tango Therapeutics Inc.TNGX | 0%new |
| 10 | Pioneer Power Solutions Inc.PPSI | 0%new |